PERCEPTIVE ADVISORS LLC
Q2 2020 13F-HR/A Holdings
Net value change ($000)
+2,331,569
(60.7%)
New positions
33
Sold out positions
23
Turnover %
13.2%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q1 2020
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| FOLD | 147,065 | 63.2% |
| VAC | 126,978 | 290.9% |
| MyoKardia, Inc. | 73,176 | 118.8% |
| Athenex, Inc. | 66,674 | 74.7% |
| Mirati Therapeutics, Inc. | 61,204 | 24.0% |
| Global Blood Therapeutics, Inc. | 58,914 | 19.0% |
| Forma Therapeutics Holdings, Inc. | 58,113 | NEW |
| SpringWorks Therapeutics, Inc. | 53,525 | 56.9% |
| ZOGENIX, INC. | 47,152 | 55.2% |
| QUOTIENT LTD | 45,847 | 87.3% |
Top Reduces (Value $000, Stocks/ETFs)
| REGN | -29,709 | -76.1% |
| IOVA | -25,173 | -7.2% |
| TBPH | -23,110 | -100.0% |
| RGNX | -17,145 | -100.0% |
| SOLID BIOSCIENCES INC | -16,132 | -100.0% |
| DNLI | -14,884 | -100.0% |
| TXG | -13,816 | -100.0% |
| TVTX | -13,302 | -31.5% |
| Revance Therapeutics, Inc. | -12,082 | -88.3% |
| GILD | -11,214 | -100.0% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
9,965
(0.2% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|